![conference banner](/images/conference-banner.jpeg)
Abstract
Pulmonary fibrosis is an unremitting degenerative lung disease that has an associated high mortality. The major pathological features include the growth of fibroblasts, emergence of myofibroblasts and their production of extracellular matrix that distorts the peripheral lung tissue and impairs respiratory function. Efforts to pharmacologically reduce inflammation, inhibit fibroblast growth, or matrix synthesis have not been successful in ameliorating disease. Genetic mutations associated with rare hereditary forms of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) link definitive causes to this enigmatic group of diseases. The generation of mouse models with similar genetic lesions or deficiencies is providing insight into the mechanisms that lead to fibrosis. Mutations that alter components of pulmonary surfactant or surfactant homeostasis have been associated with specific forms of ILD and/or IPF. This small but growing collection of IPF related surfactant dysfunction mutations implicate respiratory epithelial cell injury as an early event in the molecular pathogenesis and progression of fibrosis. Determining the mechanisms for genetically defined examples of IPF should be informative for investigating the larger segment of IPF where the underlying cause remains obscure.
Keywords: Transgenic mice, Gene targeted mice, ILD-Interstitial Lung Disease, IPF-Idiopathic Pulmonary Fibrosis, myofibroblasts, inhibit fibroblast growth, idiopathic pulmonary fibrosis (IPF), genetic lesions, surfactant homeostasis, epithelial cell, molecular pathogenesis, infectious agents, Less pronounced fibrosis, fibrotic elements, epithelial cell defect
Current Pharmaceutical Biotechnology
Title: Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis
Volume: 12 Issue: 9
Author(s): Stephan W. Glasser and Albert P. Senft
Affiliation:
Keywords: Transgenic mice, Gene targeted mice, ILD-Interstitial Lung Disease, IPF-Idiopathic Pulmonary Fibrosis, myofibroblasts, inhibit fibroblast growth, idiopathic pulmonary fibrosis (IPF), genetic lesions, surfactant homeostasis, epithelial cell, molecular pathogenesis, infectious agents, Less pronounced fibrosis, fibrotic elements, epithelial cell defect
Abstract: Pulmonary fibrosis is an unremitting degenerative lung disease that has an associated high mortality. The major pathological features include the growth of fibroblasts, emergence of myofibroblasts and their production of extracellular matrix that distorts the peripheral lung tissue and impairs respiratory function. Efforts to pharmacologically reduce inflammation, inhibit fibroblast growth, or matrix synthesis have not been successful in ameliorating disease. Genetic mutations associated with rare hereditary forms of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) link definitive causes to this enigmatic group of diseases. The generation of mouse models with similar genetic lesions or deficiencies is providing insight into the mechanisms that lead to fibrosis. Mutations that alter components of pulmonary surfactant or surfactant homeostasis have been associated with specific forms of ILD and/or IPF. This small but growing collection of IPF related surfactant dysfunction mutations implicate respiratory epithelial cell injury as an early event in the molecular pathogenesis and progression of fibrosis. Determining the mechanisms for genetically defined examples of IPF should be informative for investigating the larger segment of IPF where the underlying cause remains obscure.
Export Options
About this article
Cite this article as:
W. Glasser Stephan and P. Senft Albert, Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281045
DOI https://dx.doi.org/10.2174/138920111798281045 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Efficacy of Gefitinib in Patients with Advanced Non-small-cell Carcinoma of the Lung Harboring Common, Uncommon and Complex EGFR Mutations
Clinical Cancer Drugs Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer
Current Cancer Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Protein Kinases as Drug Targets in Cancer
Current Cancer Drug Targets Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial from Guest Editor [Hot topic: The Optimal Care of the Lung in the Critically Ill (Guest Editor: Ross Freebairn)]
Current Respiratory Medicine Reviews